Nanomedicine safety in preclinical and clinical development: focus on idiosyncratic injection/infusion reactions-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Nanomedicine safety in preclinical and clinical development: focus on idiosyncratic injection/infusion reactions

Published:2018-05 Issue:5 Volume:23 Page:1034-1042
ISSN:1359-6446
Container-title:Drug Discovery Today
language:en
Short-container-title:Drug Discovery Today

Author:

Moghimi Seyed Moein

Funder

Danish Agency for Science, Technology and Innovation (Det Strategiske Forskningsråd)

Danish Council for Independent Research, Technology and Production Sciences

Lundbeckfonden

International Science and Technology Cooperation of Guangdong Province

Guangzhou City

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology

Reference81 articles.

1. Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective;Moghimi;Annu. Rev. Pharmacol. Toxicol.,2012

2. The similarity question for biological and non-biological complex drugs;Crommelin;Eur. J. Pharm. Sci.,2015

3. The big picture on nanomedicine: the state of investigational and approved nanomedicine products;Etheridge;Nanomedicine,2013

4. Nanotherapeutics in the EU: an overview on current state and future directions;Hafner;Int. J. Nanomed.,2014

5. Phase I clinical trial and pharmacokinetic evaluation of doxorubicin carried by polyisohexylcyanoacrylate nanoparticles;Kattan;Invest. New Drugs,1992

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting Tumor-Associated Macrophages with the Immune-Activating Nanomedicine for Achieving Strong Antitumor Activity with Rapid Clearance from the Body;ACS Nano;2024-08-14

2. Exemplifying interspecies variation of liposome in vivo fate by the effects of anti-PEG antibodies;Acta Pharmaceutica Sinica B;2024-08

3. Anti-Poly(ethylene glycol) (PEG) Antibodies: From Where Are We Coming and Where Are We Going;Journal of Nanotheranostics;2024-07-29

4. Rediscovery of mononuclear phagocyte system blockade for nanoparticle drug delivery;Nature Communications;2024-05-22

5. Risk Assessment and Management in Nanotoxicology;Environmental Nanotoxicology;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3